SHELTON, Conn., Feb. 16, 2016 /PRNewswire/ -- NanoViricides, Inc.
(NYSE MKT: NNVC (the "Company") announced today that it has entered
into an agreement with Baylor College of
Medicine (Baylor) for the testing of its nanoviricides® drug
candidates in a small animal model of ocular virus infections.
The research will be supervised by Dr. Stephen Pflugfelder, Professor of Ophthalmology
and the James and Margaret Elkins Chair in Ophthalmology at Baylor.
Dr. Pflugfelder has extensive experience in ophthalmological
research as well as in ocular drug development, including
conducting clinical trials. The research will be performed in the
laboratories of the Department of Ophthalmology.
These animal studies will evaluate the efficacy and potency of
the Company's nanoviricides anti-viral agents in certain ocular
viral infections. The goal of these studies is to help select
clinical drug development candidates for treatment of certain
ocular viral diseases including herpes keratitis in humans.
"We are very pleased to have the Baylor
College of Medicine Department of Ophthalmology join our
efforts in developing a drug against ocular viral infections
including Herpes Keratitis," said Eugene
Seymour, MD, MPH, CEO of the Company, adding, "We believe
Dr. Pflugfelder and his lab will be able to guide us in the
IND-enabling development of our drug candidates."
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo -
http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-for-ocular-testing-of-its-drug-candidates-for-the-treatment-of-herpes-keratitis-with-the-baylor-college-of-medicine-300220439.html
SOURCE NanoViricides, Inc.